Deutsche Bank initiates coverage on Insulet with Buy rating

0 min read | Published on 23 Jun 2026, 08:59 PM |Updated on 23 Jun 2026, 09:23 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

Deutsche Bank analyst Kieran Ryan initiated coverage on Insulet Corporation with a Buy rating and a price target of $190, signaling confidence in the company's future performance.

*this image is generated using AI for illustrative purposes only.

Deutsche Bank analyst Kieran Ryan has initiated coverage on Insulet Corporation with a Buy rating and a price target of $190, signaling confidence in the medical device company's future performance. This rating highlights the firm's positive outlook on Insulet's market position and growth potential within the diabetes care sector. The initiation provides investors with a specific valuation benchmark as they assess the stock's trajectory.

Analyst Details

The coverage was initiated by Kieran Ryan of Deutsche Bank. The firm set a specific price target to guide investor expectations.

Firm	Analyst	Rating	Price Target
Deutsche Bank	Kieran Ryan	Buy	$190

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific growth drivers in the diabetes care sector justify the $190 price target?

How might Insulet's competitive landscape evolve in response to this bullish outlook?

What upcoming product launches or innovations could further strengthen Insulet's market position?

Truist maintains Buy on Insulet, cuts price target to $219

0 min read | Published on 12 Jun 2026, 07:58 PM |Updated on 12 Jun 2026, 07:58 PM

Reviewed by

Radhika SScanX News Team

Add as a preferred
source on Google

Key Highlights

Truist Securities analyst Richard Newitter maintained a Buy rating on Insulet (NASDAQ: PODD) but lowered the price target from $250 to $219, adjusting the valuation outlook while retaining a positive stance on the stock.

*this image is generated using AI for illustrative purposes only.

Truist Securities analyst Richard Newitter has maintained a Buy rating on Insulet (NASDAQ: PODD) while reducing the price target to $219 from the previous $250. The adjustment reflects a revised outlook on the stock's valuation potential despite the continued positive recommendation.

Rating and Price Target Details

The decision to keep the Buy rating indicates confidence in Insulet's underlying business performance and market position. However, the reduction in the price target suggests a recalibration of expected returns based on current market conditions or company-specific factors.

Metric	Value
Rating	Buy
Previous Price Target	$250
New Price Target	$219

Insulet continues to be viewed favorably by the firm, with the lower price target potentially offering a revised entry point for investors considering the stock.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

What specific market conditions or company-specific factors led to the recalibration of Insulet's valuation potential?

How might this price target reduction influence investor sentiment and short-term stock performance?

What are the key growth drivers for Insulet that support the continued Buy rating despite the lower price target?